RaveDAO (RAVE) surged 16.25% to a six-week high of $0.369, breaking out from a long consolidation phase. This rally was driven mainly by speculative demand, with derivatives volume rising over 211% and open interest increasing 21%, indicating strong market participation. Buyers also returned on the spot market, pushing the buy volume higher and supporting the price momentum. If demand sustains, RAVE could test resistance levels at $0.40 and $0.48, but a drop below $0.28 may occur if speculative interest fades.
Celldex Therapeutics received a Buy rating upgrade from H.C. Wainwright, with the price target raised to $64 from $42, following successful Phase 3 clinical trials of barzolvolimab. The drug showed rapid and lasting benefits for patients with a chron...
dLocal offers a unified payment gateway enabling global merchants to access over 60 emerging markets, fueling strong transaction volume and revenue growth. Although its take-rate has compressed to 0.71%, this is mainly due to merchant mix, volume tie...
Qualcomm introduced its Snapdragon 8 Elite Gen 6 chipsets, designed for high-end Android smartphones with enhanced on-device AI capabilities. Built using TSMC's 2-nanometer process, these chips target premium brands like Motorola, Xiaomi, and ZTE ami...
Simmons First National Corporation announced it will host an Investor Day on December 10, 2026, in New York City. The event will feature presentations by CEO Jay Brogdon, CFO Daniel Hobbs, and other executives discussing the company's strategic prior...
Quest Diagnostics announced it will release its third quarter 2026 financial results on October 22, 2026, before the market opens. The company will hold a conference call at 8:30 a.m. Eastern Time to discuss the results, accessible via phone and webc...
